Tumor drug production plant to start trials in October

A technician verifies data at Guizhou Lianke Zhongbei Pharmaceutical Technology Co. [Photo/WeChat of Wudang]

A new pharmaceutical plant that will produce tumor treatment drugs in the Wudang district of Guiyang — capital city of Southwest China’s Guizhou province — is scheduled to start trial production in October, according to local officials.

The plant will be operated by Guizhou Lianke Zhongbei Pharmaceutical Technology Co, which focuses on developing drugs.

Officials said the construction of the plant began in October, 2018 and it will cost 310 million yuan ($43.81 million), with a production area covering 314,000 square meters.

Two production lines are being built, which will adopt international advanced man-machine isolation technologies. These can realize real-time production monitoring, data collection and unmanned production.

They are expected to have annual production capacity of 12 million bottles of small-capacity injections and 3.85 million bottles of freeze-dried powder injections and the annual output value is projected to be 1.71 billion yuan.

Currently, the plant is still under construction, but Miao Xuhui, its project manager, said that 95 percent of the main structure and 90 percent of the fittings have been completed.

Meanwhile, the production line equipment ordered in Shanghai, Hunan and Shandong has arrived and undergone testing. 

Miao added that the plant will complete equipment installation and commissioning in May.